Drugs / EXC 001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT01494922 | Dec 2011 → Sep 2013 | keloid formation | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01037413 | Dec 2009 → Apr 2010 | keloid formation | Pfizer | Completed | Met primary |
| Phase 2 | NCT01037985 | Dec 2009 → Jul 2010 | keloid formation | Pfizer | Completed | Missed primary |
| Phase 2 | NCT01038297 | Dec 2009 → Jul 2010 | keloid formation | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01346969 Comparator | Jun 2011 → Apr 2012 | keloid formation | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-11-02 | Ionis Pharmaceuticals | Isis To Receive $1.25 Million Payment As Pfizer Continues Development Of EXC 001 ionis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXC 001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01494922 ↗ |
| Known as | PF-06473871 | “EXC 001 (currently called PF-06473871)” NCT01494922 ↗ |